Eldrin F. Lewis

33.8k total citations · 8 hit papers
223 papers, 16.8k citations indexed

About

Eldrin F. Lewis is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Eldrin F. Lewis has authored 223 papers receiving a total of 16.8k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Cardiology and Cardiovascular Medicine, 32 papers in Pulmonary and Respiratory Medicine and 25 papers in Surgery. Recurrent topics in Eldrin F. Lewis's work include Heart Failure Treatment and Management (111 papers), Cardiovascular Function and Risk Factors (66 papers) and Cardiac pacing and defibrillation studies (39 papers). Eldrin F. Lewis is often cited by papers focused on Heart Failure Treatment and Management (111 papers), Cardiovascular Function and Risk Factors (66 papers) and Cardiac pacing and defibrillation studies (39 papers). Eldrin F. Lewis collaborates with scholars based in United States, Canada and United Kingdom. Eldrin F. Lewis's co-authors include Scott D. Solomon, Marc A. Pfeffer, John J.V. McMurray, Lâle Tokgözoğlu, Julie E. Buring, Göran K. Hansson, John Deanfield, Lina Badimón, Márcio Sommer Bittencourt and Peter Libby and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Eldrin F. Lewis

210 papers receiving 16.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atherosclerosis

2019 2.0k citations Eldrin F. Lewis et al. profile →
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015 1.7k citations Marc A. Pfeffer, Rafael Díaz et al. profile →
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

2009 1.4k citations Marc A. Pfeffer, Eldrin F. Lewis et al. profile →
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes

2004 971 citations Eldrin F. Lewis, Marc A. Pfeffer et al. profile →
Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association

2018 548 citations Eldrin F. Lewis et al. Circulation profile →
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association

2016 539 citations Gregg C. Fonarow, Eldrin F. Lewis et al. Circulation profile →
Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis

2013 525 citations Eldrin F. Lewis et al. profile →
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction

2015 335 citations Scott D. Solomon, Brian Claggett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eldrin F. Lewis United States	56	7.4k	3.7k	3.3k	2.2k	2.0k	223	16.8k
Chim C. Lang United Kingdom	65	8.8k 1.2×	2.6k 0.7×	3.0k 0.9×	1.7k 0.8×	2.3k 1.1×	394	16.1k
Frank Ruschitzka Switzerland	61	14.8k 2.0×	3.8k 1.0×	1.9k 0.6×	2.7k 1.2×	1.9k 0.9×	384	21.4k
Gianni Tognoni Italy	76	11.6k 1.6×	4.1k 1.1×	2.8k 0.9×	3.8k 1.7×	2.2k 1.1×	263	23.8k
Inder S. Anand United States	81	17.6k 2.4×	2.9k 0.8×	2.7k 0.8×	3.0k 1.4×	1.6k 0.8×	420	23.2k
Roberto Latini Italy	77	11.2k 1.5×	3.6k 1.0×	1.9k 0.6×	3.5k 1.6×	3.0k 1.5×	424	23.1k
Wiek H. van Gilst Netherlands	68	11.8k 1.6×	2.8k 0.7×	2.4k 0.7×	1.4k 0.6×	3.6k 1.8×	475	20.4k
Susan R. Heckbert United States	75	10.0k 1.3×	2.5k 0.7×	3.8k 1.2×	1.7k 0.8×	1.6k 0.8×	479	21.7k
G. Michael Felker United States	83	17.3k 2.3×	4.3k 1.1×	1.8k 0.6×	4.2k 1.9×	2.5k 1.2×	417	24.0k
Robert J. Mentz United States	63	9.9k 1.3×	2.5k 0.7×	4.2k 1.3×	2.3k 1.1×	1.7k 0.8×	579	15.7k
Justin A. Ezekowitz Canada	60	11.3k 1.5×	1.6k 0.4×	1.5k 0.5×	1.8k 0.8×	1.2k 0.6×	415	15.8k

Countries citing papers authored by Eldrin F. Lewis

Since Specialization

Citations

This map shows the geographic impact of Eldrin F. Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eldrin F. Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eldrin F. Lewis more than expected).

Fields of papers citing papers by Eldrin F. Lewis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eldrin F. Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eldrin F. Lewis. The network helps show where Eldrin F. Lewis may publish in the future.

Co-authorship network of co-authors of Eldrin F. Lewis

This figure shows the co-authorship network connecting the top 25 collaborators of Eldrin F. Lewis. A scholar is included among the top collaborators of Eldrin F. Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eldrin F. Lewis. Eldrin F. Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Henderson, Alasdair, Inder S. Anand, Akshay S. Desai, et al.. (2025). Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF. European Heart Journal - Cardiovascular Pharmacotherapy. 11(7). 574–589.

Bacong, Adrian Matias, Abha Khandelwal, Dhruv S. Kazi, et al.. (2025). Heart Disease Mortality in the United States, 1970 to 2022. Journal of the American Heart Association. 14(13). e038644–e038644. 5 indexed citations

Lassen, Mats Christian Højbjerg, John W. Ostrominski, Brian Claggett, et al.. (2025). Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 13(8). 102498–102498. 2 indexed citations

Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Race in Heart Failure. JACC Heart Failure. 13(1). 58–71.

Reeder, Christopher, Brian Claggett, Pulkit Singh, et al.. (2024). Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials. Circulation Heart Failure. 18(1). e012514–e012514. 1 indexed citations

Causland, Finnian R. Mc, Martina M. McGrath, Brian Claggett, et al.. (2024). Acute Changes in Kidney Function and Outcomes Following an Acute Myocardial Infarction: Insights from PARADISE-MI. European Journal of Heart Failure. 26(9). 1984–1992.

Petrie, Mark C., Jean L. Rouleau, Brian Claggett, et al.. (2024). Pulmonary Congestion and Left Ventricular Dysfunction After Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation. 149(4). 335–338. 1 indexed citations

Jering, Karola, Brian Claggett, Marc A. Pfeffer, et al.. (2023). Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial. Circulation Heart Failure. 16(5). e010259–e010259. 14 indexed citations

Mueller, Adrienne, Roy Lan, Cati Brown‐Johnson, et al.. (2023). Opportunities to Increase Science of Diversity and Inclusion in Clinical Trials: Equity and a Lack of a Control. Journal of the American Heart Association. 12(24). e030042–e030042. 3 indexed citations

10.

Granger, Bradi B., Lisa A. Kaltenbach, Gregg C. Fonarow, et al.. (2022). Health System–Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial. Journal of Cardiac Failure. 28(8). 1355–1361. 6 indexed citations

11.

Wolsk, Emil, Brian Claggett, Rafael Díaz, et al.. (2022). Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. Journal of the American Heart Association. 11(8). e021327–e021327. 3 indexed citations

12.

Toto, Robert D., et al.. (2020). A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. Journal of the American Society of Nephrology. 32(2). 469–478. 1 indexed citations

13.

Castro, Renata Rodrigues Teixeira de, Emer Joyce, Neal K. Lakdawala, et al.. (2019). Patients report more severe daily limitations than recognized by their physicians. Clinical Cardiology. 42(12). 1181–1188. 4 indexed citations

14.

Chandra, Alvin, Eldrin F. Lewis, Brian Claggett, et al.. (2018). Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure. JAMA Cardiology. 3(6). 498–498. 75 indexed citations

15.

Greene, Stephen J., Gregg C. Fonarow, Scott Solomon, et al.. (2015). Global Variation in Clinical Profile, Management, and Post-Discharge Outcomes Among Patients Hospitalized For Worsening Chronic Heart Failure: Findings from the ASTRONAUT trial. European Journal of Heart Failure. 17(6). 591–600. 47 indexed citations

16.

Bello, Natalie A., Eldrin F. Lewis, Akshay S. Desai, et al.. (2015). Increased Risk of Stroke with Darbepoetin Alfa in Anaemic Heart Failure Patients with Diabetes and Chronic Kidney Disease. European Journal of Heart Failure. 17(11). 1201–1207. 34 indexed citations

17.

Lam, Carolyn S.P., Margaret McEntegart, Brian Claggett, et al.. (2015). Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction: Insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 17(3). 301–312. 48 indexed citations

18.

Lamas, Gervasio A., Christine Goertz, Robin Boineau, et al.. (2014). Disodium EDTA Chelation for Post Myocardial Infarction Patients. The Journal of Alternative and Complementary Medicine. 20(5). A2–A2. 1 indexed citations

19.

Lamas, Gervasio A., Robin Boineau, Christine Goertz, et al.. (2014). Oral High-Dose Multivitamins and Minerals Alone and in Combination with Chelation Therapy for Coronary Disease: A Randomized Clinical Trial. The Journal of Alternative and Complementary Medicine. 20(5). A2–A3. 1 indexed citations

20.

Lewis, Eldrin F., Gervasio A. Lamas, Eileen O’Meara, et al.. (2006). Characterization of Health-Related Quality of Life in Heart Failure Patients with Preserved Versus Low Ejection Fraction in CHARM. European Journal of Heart Failure. 9(1). 83–91. 179 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact